Photo by freestocks
Despite over 700 well-turned-out attendees, 150 speakers and 56 corporate sponsors, the recent three-day Fierce Pharma Engage conference in San Diego, part of the yearly “Fierce Pharma Week,” revealed that all is not well in Pharmaville.
Despite a well-funded, future-gazing event full of young and ambitious Pharma believers, three doubts fester behind marketing bravado:
*The End Prescription Drug Ads Now Act introduced in the US Congress last summer which could limit or stop Direct-to-Consumer (DTC), Ask Your Doctor advertising
*Consumers and healthcare professionals (HCPs) are tiring of prescription drug marketing and increasingly impervious to its sales messages.
*”Misinformation.” While Pharma misinformation from its huge news/tech footprint worries many, Pharma also worries misinformation. From whom—kale sellers?
Here were other themes of the event, which wrapped up on April 24.
1. AI Will Improve Stressed Interactions with HCPs
It comes as no shock that HCPs are not fans of Pharma marketing whether online or from in-person office calls. Some refuse to see reps altogether and many ignore or block Pharma online messaging (as do consumers.)
HCPs are especially miffed, according to conference sessions, by inappropriate messaging– “intro-to-drug” info sent after someone has already met with a rep or general, PCP-appropriate info when the HCP is a specialist. Hello?
But not to worry. Merck’s new “agentic” AI app in partnership with Google Cloud, cited at the conference, allows drugmakers to know exactly where in the sales “journey”* their targeted HCP is. The AI app will signal to “stop” when a HCP has received their fill of info… and annoyance..
Targeting HCPs from their patient’s initial “journey” to the success of prescription “fulfillment” is so fraught these days, so impeded, that drugmakers are now targeting lab and screening personnel who see the patient first–an end run around HCPs.
* “journey” is the Pharma word of the year
2. Selling Diseases Creates New Markets
As anyone who watches TV knows, monetizing diseases is a tried and true Pharma marketing agenda. A session at the conference called “Shaping New Markets, One Rare Condition at a Time” confirmed the stealth, hypochondria selling spin.
“In rare disease, marketers aren’t just promoting treatments—they’re creating entirely new markets, redefining education, and rewriting the playbook for engagement. This session explores how pharma leaders are shaping awareness before launch…and driving access in conditions that have long gone untreated. Hear how collaboration between marketing, medical, and patient advocacy can transform awareness into action in even the rarest spaces,” said one session description.
Recently, a bill was introduced in the Maryland legislature to force “disease awareness” ad campaigns that don’t mention the drug being sold and “patient advocacy groups” to disclose the Pharma funding behind their communications.
3. Influencers Will Take Over Marketing
Have you noticed the new, aggressive phenomenon of telehealth medicine–manufacturer-direct channels/systems, home delivery, patient access/ insurance programs and digital “education”? Meant to bypass traditional medical gatekeepers?
As Pharma-owned telehealth operations appear in strip malls and proliferate online, more than 900 CVS stores and 500 Walgreens stores have closed in the US. Who needs the “middlemen” says Pharma.
So, it is no surprise that Pharma, according to Fierce Pharma Engage programming, is shifting its marketing from traditional DTC, consumer advertising to Direct-to-Patient or “DTP” marketing from its own funded channels–bypassing online/broadcast ads and, likely, FDA regulation.
Pharma’s new focus–influencer-originated DTP ads– will be “my” stories like “my psoriasis” and “my fibromyalgia”— revealed conference sessions.
Of course, personal health “journey” stories already propel social media and Pharma celebrity advertising from people like Naomi Watts, Serena Williams, Sarah Jessica Parker, Octavia Spencer or Sofia Vergara.
4. Missing This Year: GLP-1 Agonists and Consumer Trust
Some were surprised that GLP-1 agonists, featured at the January Fierce Pharma/ Fierce Biotech-hosted J.P. Morgan Healthcare Conference in San Francisco, did not constitute a separate session this April at the Fierce Pharma Engage event. Have the blockbusters reached their profit potential? Have safety signals clouded their financial future? Or have non-Pharma “me-too” drugs stolen market share?
Also, missing this year, despite aggressive new partnerships and bold marketing rollouts, is trust from HCPs and consumers who say they have been courted by drugmakers enough.